Navigation Links
Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Date:9/24/2013

LONDON, Sept. 24, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the Company has begun a two-week clinical trial designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

The trial, which began on September 23rd, 2013, is being conducted in partnership with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH").

Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake is working on a new intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S. According to the Centers for Disease Control and Prevention, 16,651 people died from prescription opioid overdose in the U.S. in 2010, a significant increase from the 4,030 overdose deaths in 1999.

Assuming favorable outcomes from this study, NIDA plans to file an IND for a larger study. The expected goal of Lightlake's partnership with NIDA is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.

"We are very pleased to begin our trial with NIDA as we believe this is a key step that will help us to formally deliver an intranasal naloxone spray aimed at reversing opioid overdoses to the healthcare community," stated Dr. Roger Crystal, CEO of Lightlake. "Naloxone is the ideal opioid antagonist and we are confident that the data from this trial can also be used to supply critical data for other Lightlake studies that involve va
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
2. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
3. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
4. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
5. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
6. Adheron Therapeutics Names New Senior Leadership
7. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
8. Echo Therapeutics Sends Response to Shareholder Letter
9. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
10. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
11. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Human Longevity, Inc. (HLI), a ... on extending the healthy, high performance human life span, ... Ph.D., an expert in machine learning and machine translation ... HLI from Google where he was Distinguished Research Scientist ... directly to HLI Co-Founder and CEO, J. Craig ...
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is investigating ... ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors are ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... officers and/or directors have violated Sections 10(b) and 20(a) ... On July 29, 2014, Impax Laboratories, Inc. (the ...
(Date:7/29/2014)... Oregon , July 29, 2014 ... "Global surgical equipment market (types, applications and geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... to reach $12.1 billion by 2020 registering a CAGR ... to the breakthrough achieved by the electro surgical devices ...
(Date:7/29/2014)... July 29, 2014 Philadelphia’s newest entrepreneurial incubation ... get their start. The Innovation Center @3401 , a ... University City Science Center to help attract and nurture ... Monday, July 28. , The Innovation Center ... and Market Streets, is the new home of DreamIt ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
... Global consultant Tom Koulopoulos said at the Fusion2006 CEO-CIO ... work they do that does not support their core competency ... expect, a discussion of outsourcing versus doing work in house ... the Delphi Group founder to tap his experience in IT ...
... Robert Paulos, associate director for the IceCube project, holds ... IceCube neutrino telescope. Photo courtesy of the Ice Cube ... of scientists and engineers has taken a major step ... cosmic neutrino observatory, harnessing a sophisticated hot-water drill to ...
... have been infected with the H5N1 avian influenza virus, mostly ... virus does not spread easily from its pioneering human hosts ... a study of cells in the human respiratory tract reveals ... that makes it difficult for the virus to jump from ...
Cached Biology Technology:IT outsourcing according to Tom Koulopoulos, part 1 2IT outsourcing according to Tom Koulopoulos, part 1 3Polar neutrino observatory construction leaps ahead 2Polar neutrino observatory construction leaps ahead 3Polar neutrino observatory construction leaps ahead 4UW shows why avian flu hasn't spread among humans yet 2UW shows why avian flu hasn't spread among humans yet 3
(Date:7/28/2014)... of a new study suggest two ways to effectively address ... well in obese women, compared to women of a normal ... method, researchers say, but as the population has increased in ... for obese women. Studies have consistently found that obesity has ... may in turn affect how well the pill prevents pregnancy. ...
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
(Date:7/28/2014)... HOUSTON (July 28, 2014) Rice University researchers ... chains of varying flexibility that can be used as ... visual proof that "bead-spring" polymers, introduced as theory in ... flexible as required and should be of interest to ... , The work led by Rice chemical and biomolecular ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Seeing is bead-lieving 2
... new gene could lead to better bug-resistant plants. ... the cover of this week,s Proceedings of the ... could re-learn a thing or two from their wild ... losing beneficial traits common to wild tomatoes. Anthony Schilmiller, ...
... Sept. 17, 2012Whether your neighbourhood is conducive to ... according to a new study by researchers at ... Evaluative Sciences. Researchers found this risk was ... neighbourhoods. A new immigrant living in a less ...
... study suggests there are two root causes of a type ... already have sparked a clinical trial, may guide development of ... CF. Almost half of patients with CF will ... develop it in their teens. In addition to the health ...
Cached Biology News:New gene could lead to better bug-resistant plants 2Risk of developing diabetes higher in neighborhoods that aren't walk-friendly: Study 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3
... Agilents G1979A multisignal output accessory ... multiple data systems in laboratories with ... unprocessed digital MS signals from Agilent ... into analog format and transmits the ...
... DSQ II (Dual-Stage Quadrupole) Thermo Scientific ... leader in analytical instrumentation, introduces the latest ... DSQ II. Based on the proven reliability ... PolarisQ GC/MS systems, the DSQ II incorporates ...
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Contents include: Microarray hybridization chamber ... chamber top, clamp, thumbscrew) Microarray chamber user ... and are intended to be cleaned and ... with Agilents Catalog Oligo Microarray kits and ...
Biology Products: